

快速成长的药物警戒 SaaS 领导者





SaaS

这是一家快速成长的云原生 SaaS

公司，总部位于班加罗尔，在美国、英国和欧洲均设有办事处，专门为全球生命科学行业提供药物警戒 (PV) 和临床试验 IT 解决方案。

该公司提供的一体化平台集受理、病例处理、监管提交和信号检测于一体，可将 IT 成本降低 70%，合规时间缩短 30%。

公司成立于 2017 年，在印度拥有一支由 65 多名员工组成的专业化团队，为 15 个国家的 100 多家直接客户和 160 多家终端客户提供支持。

核心平台功能

- 带 AS2 网关的统一 PV 数据库
- 网络、电子邮件和 MICC 接收模块
- 案例处理、自动叙述、信号检测
- E2B R2/R3 支持和实时分析
- 集成 CTMS、EDC、eTMF、ePRO、IWRS 和 eConsent 模块

差异化

- 由人工智能驱动自动病例预订、分流和处理系统
- 端到端统一系统（与传统堆栈中的零散工具相比）
- 内置监管合规工具（如提交和报告）
- 受到印度十大制药公司前三名的信赖

战略足迹

TARGET PRICE

\$ 0

GROSS REVENUE

\$ 3,000,000

EBITDA

\$ 1,000,000

BUSINESS TYPE

软件和 SAAS

COUNTRY

印度

BUSINESS ID

L#20250961

- 在印度、美国、英国和更广泛的欧洲市场占据重要地位
- 嵌入全球 CRO，并通过合作伙伴关系（如 Wipro、Persistent、Cognizant）进行扩展
- 在 250 多项临床研究中得到积极应用

愿景

- 2025:以人工智能为主导的药物警戒工作流程自动化
- 2030 年：成为全球前十大光伏 IT 供应商，占据 30% 的市场份额

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM